Isabelle de Zegher

Vice President Integrated Solutions, at PAREXEL Informatics

50 characters or less Isabelle de Zegher is Vice President, Integrated Solutions at PAREXEL Informatics where she is responsible for engineering strategy around Digital Innovation, Big Data, BI and Advanced Analytics. She has 25 years’ experience in Life Sciences, including extensive work on cross-industry forum on integration. Isabelle holds a MD (Belgium) and an MSc in Medical Information Sciences (Stanford University). 300 characters or less Isabelle de Zegher is Vice President Integrated Solutions, at PAREXEL Informatics since 2011 where she is responsible for strategic initiatives related to Digital Innovation, Sensor platform, Artificial Intelligence and Data Sciences; she joined PAREXEL as Senior Director Technology Integration & Data Standards in 2009. She used to be the Novartis Pharma Development Chief Data Officer, after being Global Head Account Management Clinical Development & Medical Affairs for 2 years. Isabelle joined Novartis in 2005 coming from UCB Pharma where she used to be Head of Global Electronic Document Management. Before that, she worked for 8 years at Cap Gemini as a business consultant and subsequently as Director of Life Sciences Consulting, covering Hospital Sector, Public Health, Drug Regulatory Authorities and Pharmaceutical industry. She started her career as a senior researcher in a Belgium company where she managed for 5 years European Research consortia funded by the European Commission as part of the Advanced Informatics in Medicine initiative. Isabelle holds a MD and MSc in Computer Sciences from the University of Louvain, Belgium, and a MSc in Medical Information Sciences from Stanford University, USA. Throughout her career she participated as an expert to several standardization working groups at CEN, ICH and EFPIA level. She used to chair the EFPIA EHR task force and served on the CDISC Board of Directors for 3 years; she co-chaired with FDA the PhUSE - FDA CSS working group on Emerging technology and is/has been co-chairing the Big Data/ Digital Disruptors Theme for DIA Europe.

Alex Zhavoronkov

CEO of Insilico Medicine

Dr. Zhavoronkov is the CEO of Insilico Medicine, a Rockville-based leader in the next-generation artificial intelligence technologies for drug discovery, biomarker development, and aging research. At Insilico he pioneered the applications of generative adversarial networks and reinforcement learning techniques for generating the novel molecular structures with the desired properties. He was the first to develop the deep-learned multi-modal predictors of age for drug and biomarker development. He set up the R&D centers in 6 countries including the United Kingdom, Korea, Russia, Hong Kong and Taiwan and launched multiple B2B and B2C research platforms including Young.AI. Prior to founding Insilico Medicine, he worked in senior roles at ATI Technologies (acquired by AMD in 2006), NeuroG Neuroinformatics, the Biogerontology Research Foundation and YLabs.AI and established AgeNet.net competitions and Diversity.AI initiative. Since 2012 he published over 120 peer-reviewed research papers and books including “The Ageless Generation: How Biomedical Advances Will Transform the Global Economy†(Palgrave Macmillan, 2013). He is the co-organizer of the Annual Aging Research for Drug Discovery Forum and the Artificial Intelligence and Blockchain for Healthcare Forum at the Basel Life/EMBO, one of Europe's largest industry events in drug discovery. Dr. Zhavoronkov holds two bachelor degrees from Queen’s University, a master’s in Biotechnology from Johns Hopkins University, and a PhD in Physics and Mathematics from Moscow State University. He is the adjunct professor of artificial intelligence at the Buck Institute for Research on Aging.

Raymond A. Huml

IQVIA药物策略开发副总裁 生物类似药卓越中心全球生物类似药策略计划负责人

Raymond A. Huml, MS, DVM, RAC is Vice President of Strategic Drug Development and Head of Global Biosimilars Strategic Planning for IQVIA’s Biosimilars Center of Excellence. Dr. Huml has almost 30 years of experience in the clinical and biopharmaceutical industries. Dr. Huml previously held the position of Head of Global Due Diligence for Quintiles Corporate Development and identified risks associated with Quintiles global, product-based investments, which resulted in over $2.9b in capital committed to partnerships of all sizes. Previously, Dr. Huml worked in the Center for Integrated Drug Development (now Strategic Advisory Services), Biostatistics, Medical Writing, and Regulatory Affairs Departments in Quintiles (legacy) Clinical Development Services group. Dr. Huml has authored or co-authored over 70 articles, 11 book chapters and three books on topics such as due diligence, competitive intelligence, biosimilars and muscular dystrophy. In 2010, he published the first individually authored book for RAPS titled, “Introduction to the Due Diligence Process.” In 2015, Dr. Huml edited and wrote or co-wrote eight chapters for the Springer book titled, “Muscular Dystrophy: A Concise Guide”, which covers all types of MD. According to the 2017 and 2018 Springer Book Performance Reports, it was one of the “top 25% most downloaded eBooks in the relevant SpringerLink eBook Collection in 2016 (and 2017, respectively).” In 2003, he was awarded North Carolina Veterinary Medical Association's Young Veterinarian of the Year Award. In 2004, he was awarded Regulatory Affairs Professional’s Society (RAPS) New Professional Award. He has also received numerous Quintiles awards including the Distinguished Performance Award, Clinical Development Services President's Award and the Chairman's Award. Dr. Huml is a Returned Peace Corps Volunteer having served in Ghana, West Africa and currently sits on North Carolina State University’s Board of Visitors. He holds an MS in Biology from East Stroudsburg University and his DVM from North Carolina State University’s College of Veterinary Medicine and has earned the RAC (US) Certification.

Marcus HACKER

奥地利维也纳总医院核医学科主任 维也纳医科大学教授

PJ CHEN

APRINOIA Therapeutics高级副总裁